藥明生物(02269.HK)3月24日授出合共622.94萬股受限制股份
格隆匯 3 月 24日丨藥明生物(02269.HK)宣佈,於2021年3月24日,董事會已批准向承授人授出合共622.94萬股受限制股份,惟須待承授人接納及其他條件獲達成後方可作實,其中(i)473.62萬股受限制股份授予1,617名公司僱員(並非公司關連人士),並將透過根據2020年一般授權及按照規則條款向受託人發行及配發新股;及(ii)149.31萬股受限制股份乃建議向5位董事及3位附屬公司董事(為公司關連人士)授出,並將透過根據特別授權及按照規則條款向受託人發行及配發新股。
公司將向受託人發行及配發的新股份,相當於公司於本公吿日期已發行股本的約0.15%及公司於所述發行及配發後經擴大已發行股本的約0.15%。
此外,創富融資已獲委任為獨立財務顧問,以就發行及配發關連受限制股份、特別授權以及據此預期進行的交易向獨立股東提供意見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.